TY - JOUR T1 - Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomised trial JF - medRxiv DO - 10.1101/2022.05.24.22275434 SP - 2022.05.24.22275434 AU - Xiaoxia Wang AU - Alastair R Mobley AU - Otilia Tica AU - Kelvin Okoth AU - Rebecca E Ghosh AU - Puja Myles AU - Tim Williams AU - Sandra Haynes AU - Krishnarajah Nirantharakumar AU - David Shukla AU - Dipak Kotecha AU - the DaRe2THINK Trial Committees Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/25/2022.05.24.22275434.abstract N2 - Background Improving the efficiency of clinical trials is key to their continued importance in directing evidence-based patient care. Digital innovations, in particular the use of electronic healthcare records (EHR), allow for large-scale screening and follow-up of participants. However, it is critical these developments are accompanied by robust and transparent methods that can support high quality and high clinical value research.Methods The DaRe2THINK trial includes a series of novel processes, including nationwide pseudonymised pre-screening of the primary care EHR across England, digital enrolment, remote e-consent, and ‘no-visit’ follow-up by linking all primary and secondary care health data with patient-reported outcomes.Findings DaRe2THINK is a pragmatic, healthcare-embedded randomised trial testing whether earlier use of direct oral anticoagulants in patients with prior or current atrial fibrillation can prevent thromboembolic events and cognitive decline (www.birmingham.ac.uk/dare2think). This paper outlines the systematic approach and methodology employed to define patient information and outcome events. This includes transparency on all medical code lists and phenotypes used in the trial across a variety of national data sources, including Clinical Practice Research Datalink Aurum (primary care), Hospital Episode Statistics (secondary care) and the Office for National Statistics (mortality).Interpretation Co-designed by a patient and public involvement team, DaRe2THINK presents an opportunity to transform the approach to randomised trials in the setting of routine healthcare, providing high-quality evidence generation in populations representative of the community at-risk.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form (www.icmje.org/coi_disclosure.pdf) and declare: Dr. Wang and Mr. Mobleys posts are funded by the National Institute of Health Research (NIHR) (130280). Dr. Țicas post was funded by the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074) and a grant from Amomed Pharma, outside the submitted work. Dr. Okoth has nothing to disclose. Dr. Ghosh reports grants from NIHR, during the conduct of the study. Dr. Myles has nothing to disclose. Dr. Williams has nothing to disclose. Mrs. Haynes reports a grants from NIHR (130280), during the conduct of the study. Prof. Nirantharakumar reports grants from NIHR, during the conduct of the study; and research grants from UKRI/MRC, Kennedy Trust for Rheumatology Research, Health Data Research UK, Wellcome Trust, European Regional Development Fund, Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, South Asian Health Foundation, Vifor Pharma, College of Police, and CSL Behring, outside the submitted work; and consulting fees from Boehringer Ingelheim, Sanofi, CEGEDIM, MSD and holds a leadership/fiduciary role with NICST, a charity and OpenClinical, a Social Enterprise; outside the submitted work. Dr. Shukla reports grants from NIHR (130280), during the conduct of the study; and grants from Pfizer outside the submitted work. Prof. Kotecha reports grants from NIHR (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), and the European Society of Cardiology supported by educational grants from Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre and British Heart Foundation/University of Birmingham Accelerator Award (STEEER-AF NCT04396418). In addition, he has received a research grant to his institution from Pfizer; and research grants and advisory board fees from Bayer, Amomed and Protherics Medicines Development; all outside the submitted work.Clinical TrialClinicaltrials.gov (NCT04700826) ISRCTN (21157803) EudraCT (2020-005774-10)Clinical Protocols https://www.birmingham.ac.uk/d2t Funding StatementThe DaRe2THINK trial is funded by the National Institute of Health Research (NIHR 130280). Medications in the trial are funded by the National Health Service (UK Department of Health and Social Care).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NHS Health Research Authority and North East - Tyne & Wear South Research Ethics Committee have given approval for this work (REC number: 21/NE/0021; IRAS project ID: 290420). Regulatory approval has been given by the Medicines and Healthcare products Regulatory Agency (MHRA CTA 21761/0364).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is presented in the manuscript - this paper provides all codes used in the trial (see appendix) https://www.birmingham.ac.uk/d2t ER -